Cargando…

Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2–infected patient

Detalles Bibliográficos
Autores principales:	Stalder, Gregoire, Alberio, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	Blood Work
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426644/ https://www.ncbi.nlm.nih.gov/pubmed/32790855 http://dx.doi.org/10.1182/blood.2020006228

Ejemplares similares

Hemophagocytic lymphohistiocytosis in SARS-CoV-2 infection
por: Dewaele, Klaas, et al.
Publicado: (2020)

Morphological changes in a case of SARS-CoV-2 infection
por: Jones, John R., et al.
Publicado: (2020)

Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2–associated multisystem inflammatory syndrome
por: Lee, Won Sok, et al.
Publicado: (2020)

Post–SARS-CoV-2 vaccination acute hemolysis in an older man: don’t forget to look at the blood smear
por: Duchemann, Boris, et al.
Publicado: (2021)

Lichen planus after SARS-CoV-2 infection treated with lopinavir/ritonavir()
por: Gimeno Castillo, Javier, et al.
Publicado: (2021)

Hypersegmented granulocytes and COVID-19 infection
por: Salib, Christian, et al.
Publicado: (2020)

COVID-19–induced atypical pulmonary lymphocytes
por: Vergé, Véronique, et al.
Publicado: (2020)

Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications
por: Agarwal, Shubham, et al.
Publicado: (2020)

Pseudoreticulocytosis in a patient with myelodysplastic syndrome
por: De Rossi, Noemy, et al.
Publicado: (2021)

Neutrophilic inclusions after gelfoam embolization
por: Senzel, Lisa, et al.
Publicado: (2020)

Severe transient pancytopenia with dyserythropoiesis and dysmegakaryopoiesis in COVID-19–associated MIS-C
por: Mariani, Rachel, et al.
Publicado: (2020)

Pyruvate kinase deficiency in a newborn with extramedullary hematopoiesis in the skin
por: Voit, Richard A., et al.
Publicado: (2020)

Concurrent COVID-19 and babesiosis in an older, splenectomized patient
por: Jacobs, Jeremy W., et al.
Publicado: (2021)

A unique report of breast intravascular NK/T-cell lymphoma mimicking breast carcinoma
por: Zhou, Luting, et al.
Publicado: (2022)

Marked stress dyspoiesis secondary to sepsis and extracorporeal membrane oxygenation
por: Boyd, Jonathan D., et al.
Publicado: (2016)

Curious beads for a clinical pearl
por: Decker, Julien, et al.
Publicado: (2014)

COVID monoclonal antibody therapy detected by serum immunofixation electrophoresis
por: Shaver, Aaron C., et al.
Publicado: (2022)

Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic
por: Lory, Pauline, et al.
Publicado: (2022)

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura
por: Shah, Hridaya, et al.
Publicado: (2022)

Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
por: Uzunova, Katya, et al.
Publicado: (2020)

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
por: Cheng, Chien-Yu, et al.
Publicado: (2020)

Liquen plano en una paciente tras SARS-CoV-2 tratado con lopinavir/ritonavir
por: Gimeno Castillo, Javier, et al.
Publicado: (2021)

Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir
por: Bolcato, Giovanni, et al.
Publicado: (2020)

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
por: Blixt, Lisa, et al.
Publicado: (2022)

Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies
por: Davis, James A., et al.
Publicado: (2023)

Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir
por: Gonzalez-García, Ruben, et al.
Publicado: (2023)

New blood donors in times of crisis: Increased donation willingness, particularly among people at high risk for attracting SARS‐CoV‐2
por: Spekman, Marloes L. C., et al.
Publicado: (2021)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia
por: Bellusci, Lorenza, et al.
Publicado: (2022)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
por: Sheahan, Timothy P., et al.
Publicado: (2020)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy
por: Atanackovic, Djordje, et al.
Publicado: (2022)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection
por: Yan, Dan, et al.
Publicado: (2020)

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
por: Lecronier, Marie, et al.
Publicado: (2020)

Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome
por: Hraiech, Sami, et al.
Publicado: (2020)

No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation
por: Cappy, Pierre, et al.
Publicado: (2020)

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset
por: Perreault, Josée, et al.
Publicado: (2020)

Surrogate test performance for SARS‐CoV‐2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
por: Wendel, Silvano, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gir8gv43oe951gmon6lmnp2p7f